- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06166836
a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tumors
January 17, 2024 updated by: InxMed (Shanghai) Co., Ltd.
A Phase 1b/II, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of D-1553 Combined With IN10018 in Subjects With Locally Advanced or Metastatic Solid Tumors With KRAS G12C Mutation
This is a phase 1b/II, open-label study to evaluate the safety, tolerability, pharmacokinetics and antitumor activities of D-1553 in combination with IN10018 in subjects with locally advanced or metastatic solid tumor with KRAS G12C mutation.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
This study includes 2 phases: Phase Ib-Dose Escalation and Phase II-Dose Expansion.
Phase Ib-Dose Escalation part will enroll at least 6 subjects to identify the safety and RP2D of D1553 in combination with IN10018 in KRAS G12C mutant solid tumors.
Phase II-Dose Expansion part contains 3 cohorts with cohort A to enroll advanced colorectal cancer (CRC) with KRAS G12C mutation, cohort B to enroll advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation, and cohort C to enroll other advanced solid tumors with KRAS G12C mutation.
Phase II study is to evaluate the safety and antitumor activities of D-1553 in combination with IN10018 in KRAS G12C mutant solid tumors.
The sample size in each cohort is estimated per Simon's 2-stage design.
In Cohort A, when Simon's 2-stage study achieved statistical hypothesis, an open-label, randomized study will be conducted for factorial analysis to evaluate the contribution of IN10018 in the combination regimen.
Study Type
Interventional
Enrollment (Estimated)
140
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Shu Fang
- Phone Number: 86-15933968623
- Email: shu.fang@inxmed.com
Study Contact Backup
- Name: Lily Li
- Phone Number: 86-13911551669
- Email: lily.li@inxmed.com
Study Locations
-
-
-
Bengbu, China
- Recruiting
- First Affiliated Hospital of Bengbu Medical College
-
Contact:
- Mulin Liu
-
Changsha, China
- Recruiting
- Hunan Cancer hospital
-
Contact:
- Yongzhong Luo
-
Fuzhou, China
- Recruiting
- Fujian cancer hospital
-
Contact:
- Rongbo Lin
-
Ganzhou, China
- Recruiting
- First Affiliated hospital of GANNAN Medical University
-
Contact:
- Huaqiu Shi
-
Nanjing, China
- Recruiting
- General Hospital of Eastern Theater Command
-
Contact:
- Tangfeng LV
-
Wuhan, China
- Recruiting
- Renmin Hospital of Wuhan University
-
Contact:
- Ximing Xu
-
Xuzhou, China
- Recruiting
- XuZhou Central Hospital
-
Contact:
- Yuan Yuan
-
Zhengzhou, China
- Recruiting
- Henan Cancer Hospital
-
Contact:
- Ying Liu
-
Zhengzhou, China
- Recruiting
- The First Affiliated hospital of Zhengzhou University
-
Contact:
- Xingya Li
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310005
- Recruiting
- Zhejiang Cancer Hospital
-
Contact:
- Zhengbo Song, MD
-
Contact:
- Yiping Zhang
-
Principal Investigator:
- Liming Zhu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Men or women aged ≥ 18 years at the time of signing the informed consent form.
- Subjects with pathologically confirmed locally advanced or metastatic solid tumors.
- Confirmed positive KRAS G12C mutation in tumor tissue or other biospecimens (only for phase1b) containing cancer cells or DNA.
- Tumor types in different phases and cohorts: 1) Phase 1b: subjects with locally advanced or metastatic solid tumors who have progressed on or failed in standard therapy, and no standard treatment is available. 2) Phase II Cohort A: subjects with locally advanced or metastatic CRC. 3) Phase II Cohort B: subjects with locally advanced or metastatic NSCLC. 4) Phase 2 Cohort C: subjects with other locally advanced or metastatic solid tumors.
- Has measurable lesions at baseline according to RECIST 1.1 criteria.
- Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Adequate bone marrow, liver, renal, and coagulation function within 7 days prior to the first dose.
Exclusion Criteria:
- Prior KRAS G12C inhibitors treatment.
- Have known symptoms of spinal cord compression, instable or symptomatic central nervous system (CNS) metastases, and/or carcinomatous meningitis.
- Have a history of stroke or other serious cerebrovascular diseases within 12 months prior to the first dose.
- Have had interstitial lung disease or any active infection requiring systemic treatment within 14 days prior to the first dose.
- Has a history of severe cardiovascular disease such as acute myocardial infarction, severe/unstable angina, QTc prolongation, or poorly controlled hypertension.
- Haven't recovered from toxicity due to prior antitumor therapy
- Pregnant or lactating women.
- Malignant neoplasms other than study disease within 5 years prior to enrollment.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Phase 1b-Dose Escalation Part
To evaluate the safety and Recommended Phase 2 dose (RP2D) of D-1553 in combination with IN10018 in previously-treated solid tumors.
|
D1553 orally taken,600mg twice a day
IN10018 orally taken once daily at approximately the same time each day
Other Names:
|
Experimental: Phase II Cohort A-previously-treated CRC with KRAS G12C mutation(Treatmnt Group)
To evaluate the safety and antitumor efficacy of D-1553 in combination with IN10018 in previously-treated CRCs with KRAS G12C mutation.
|
D1553 orally taken,600mg twice a day
IN10018 orally taken once daily at approximately the same time each day
Other Names:
|
Active Comparator: Phase II Cohort A-previously-treated CRC with KRAS G12C mutation (Control Group)
To evaluate the safety and antitumor efficacy of D-1553 in previously-treated CRCs with KRAS G12C mutation.
|
D1553 orally taken,600mg twice a day
|
Experimental: Phase II Cohort B-treatment-naïve or previously-treated NSCLC with KRAS G12C mutation
To evaluate the safety and antitumor efficacy of D-1553 in combination with IN10018 in advanced NSCLCs with KRAS G12C mutation.
|
D1553 orally taken,600mg twice a day
IN10018 orally taken once daily at approximately the same time each day
Other Names:
|
Experimental: Phase II Cohort C-other previously-treated solid tumors with KRAS G12C mutation
To evaluate the safety and antitumor efficacy of D-1553 in combination with IN10018 in other solid tumors with KRAS G12C mutation
|
D1553 orally taken,600mg twice a day
IN10018 orally taken once daily at approximately the same time each day
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Recommended phase II dose (RP2D) of D1553 in combination with IN10018 in solid tumors with KRAS G12C mutation
Time Frame: Through study completion, approximately 3 years
|
Evaluate the number of patients with dose-limited toxicities (DLTs); Determine the RP2D of D1553 in combination with IN10018 in solid tumors with KRAS G12C mutation.
|
Through study completion, approximately 3 years
|
Objective Response Rate (ORR) of D1553 in combination with IN10018 in solid tumors with KRAS G12C mutation
Time Frame: Through study completion, approximately 3 years
|
Defined as the proportion of subjects with complete response (CR) or partial response (PR).
|
Through study completion, approximately 3 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free Survival (PFS) of D1553 in combination with IN10018 in solid tumors with KRAS G12C mutation
Time Frame: Through study completion, approximately 3 years
|
Defined as the time from the first dose of study treatment to first documentation of disease progression or to death due to any cause, whichever comes first.
|
Through study completion, approximately 3 years
|
Duration of Response (DoR) of D1553 in combination with IN10018 in solid tumors with KRAS G12C mutation
Time Frame: Through study completion, approximately 3 years
|
Defined as the time from start of the first documentation of CR or PR to the first documentation of disease progression or to death due to any cause, whichever comes first.
|
Through study completion, approximately 3 years
|
Disease Control Rate (DCR) of D1553 in combination with IN10018 in solid tumors with KRAS G12C mutation
Time Frame: Through study completion, approximately 3 years
|
Defined as the proportion of patients with CR, PR, or stable disease (SD).
|
Through study completion, approximately 3 years
|
Overall survival (OS) of D1553 in combination with IN10018 in solid tumors with KRAS G12C mutation
Time Frame: Through study completion, approximately 3 years
|
Defined as the time from the first dose of study treatment to the date of death due to any cause.
|
Through study completion, approximately 3 years
|
Number of subjects with adverse event
Time Frame: Through study completion, approximately 3 years
|
The number of subjects who experienced AEs is presented.
|
Through study completion, approximately 3 years
|
Plasma concentrations of D-1553 and IN10018 in solid tumors with KRAS G12C mutation
Time Frame: Through study completion, approximately 3 years
|
Plasma concentrations of D-1553 and IN10018
|
Through study completion, approximately 3 years
|
PK: Cmax of D-1553 and IN10018
Time Frame: Through study completion, approximately 3 years
|
Maximum concentration (Cmax)
|
Through study completion, approximately 3 years
|
PK: Cmin of D-1553 and IN10018
Time Frame: Through study completion, approximately 3 years
|
Minimum concentration (Cmin)
|
Through study completion, approximately 3 years
|
PK:t1/2 of D-1553 and IN10018
Time Frame: Through study completion, approximately 3 years
|
Elimination half-life (t1/2).
|
Through study completion, approximately 3 years
|
PK:CL/F of D-1553 and IN10018
Time Frame: Through study completion, approximately 3 years
|
apparent clearance (CL/F)
|
Through study completion, approximately 3 years
|
PK:Vd/F of D-1553 and IN10018
Time Frame: Through study completion, approximately 3 years
|
Apparent volume of distribution (Vd/F)
|
Through study completion, approximately 3 years
|
PK: AUC of D-1553 and IN10018
Time Frame: Through study completion, approximately 3 years
|
Area under the concentration-time curve (AUC)
|
Through study completion, approximately 3 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Zhengbo Song, Study Principal Investigator
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 12, 2022
Primary Completion (Estimated)
December 31, 2025
Study Completion (Estimated)
December 31, 2026
Study Registration Dates
First Submitted
December 4, 2023
First Submitted That Met QC Criteria
December 4, 2023
First Posted (Actual)
December 12, 2023
Study Record Updates
Last Update Posted (Actual)
January 18, 2024
Last Update Submitted That Met QC Criteria
January 17, 2024
Last Verified
December 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- D1553-106/IN10018-602
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Solid Tumor
-
Memorial Sloan Kettering Cancer CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States, Puerto Rico
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States, Puerto Rico
-
Sorrento Therapeutics, Inc.WithdrawnSolid Tumor | Relapsed Solid Tumor | Refractory Tumor
-
RemeGen Co., Ltd.CompletedMetastatic Solid Tumor | Locally Advanced Solid Tumor | Unresectable Solid TumorAustralia
-
Aadi Bioscience, Inc.RecruitingAdvanced Solid Tumor | Tumor | Tumor, SolidUnited States
-
Impact Therapeutics, Inc.RecruitingSolid Tumor | Advanced Solid TumorChina, Taiwan, United States, Australia
-
Partner Therapeutics, Inc.WithdrawnSolid Tumor | Solid Tumor, AdultUnited States
-
Jazz PharmaceuticalsMerck Sharp & Dohme LLCRecruitingAdvanced Solid Tumor | Metastatic Solid TumorUnited States
-
PharmaEngineNot yet recruitingAdvanced Solid Tumor | Metastatic Solid Tumor